ATE444745T1 - Verwendung von epa and dha zur sekundären prevention von schlaganfällen - Google Patents

Verwendung von epa and dha zur sekundären prevention von schlaganfällen

Info

Publication number
ATE444745T1
ATE444745T1 AT03722833T AT03722833T ATE444745T1 AT E444745 T1 ATE444745 T1 AT E444745T1 AT 03722833 T AT03722833 T AT 03722833T AT 03722833 T AT03722833 T AT 03722833T AT E444745 T1 ATE444745 T1 AT E444745T1
Authority
AT
Austria
Prior art keywords
dha
epa
stroke
secondary prevention
atherosclerosis
Prior art date
Application number
AT03722833T
Other languages
English (en)
Inventor
Philip Calder
Robert Grimble
Patrick Gallagher
Cliff Shearman
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Priority claimed from PCT/GB2003/001945 external-priority patent/WO2003092673A1/en
Application granted granted Critical
Publication of ATE444745T1 publication Critical patent/ATE444745T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
AT03722833T 2002-05-03 2003-05-02 Verwendung von epa and dha zur sekundären prevention von schlaganfällen ATE444745T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0210212.7A GB0210212D0 (en) 2002-05-03 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
GB0307625A GB2388026B (en) 2002-05-03 2003-04-02 Use of epa and dha in secondary prevention of neurological events,particulary strokes
PCT/GB2003/001945 WO2003092673A1 (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention

Publications (1)

Publication Number Publication Date
ATE444745T1 true ATE444745T1 (de) 2009-10-15

Family

ID=9936057

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03722833T ATE444745T1 (de) 2002-05-03 2003-05-02 Verwendung von epa and dha zur sekundären prevention von schlaganfällen

Country Status (6)

Country Link
JP (1) JP4688203B2 (de)
AT (1) ATE444745T1 (de)
DE (1) DE60329588D1 (de)
ES (1) ES2334656T3 (de)
GB (2) GB0210212D0 (de)
NZ (1) NZ536507A (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149617A1 (en) * 2005-11-14 2007-06-28 Deckelbaum Richard J Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
WO2007091338A1 (ja) 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 脳卒中再発予防用組成物
PL2046312T3 (pl) * 2006-07-14 2021-02-08 Kaydence Pharma As Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2
KR20110098909A (ko) * 2008-11-14 2011-09-02 보미 피. 팜로즈 동맥경화증의 치료를 위한, 순환하는 산화된 저밀도 지방단백질-베타-2-당단백질 1 복합체를 낮추는 방법
CN102421422A (zh) 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
ES2895477T3 (es) * 2009-10-23 2022-02-21 Basf As Cápsulas y comprimidos revestidos de una mezcla de aceites de ácidos grasos
CN105263321B (zh) 2013-03-28 2018-07-27 哥伦比亚大学纽约管理委员会 用omega-3甘油酯再灌注促进对用于移植的供体器官的保护
EP3263113A1 (de) * 2016-06-30 2018-01-03 Jürgen Mertin Anwendung und präparat (enthaltend colecalciferol, omega-3-fettsäure and ginkgo biloba) zur aufrechterhaltung und verbesserung kognitiver funktionen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
JP2534557B2 (ja) * 1989-03-30 1996-09-18 全国農業協同組合連合会 肉豚用飼料及び食肉用豚の生産方法
JPH05271685A (ja) * 1991-12-26 1993-10-19 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai 高度不飽和脂肪酸含有油脂組成物及び高度不飽和脂肪酸を含有するグリセリド油の製造方法
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
JPH1180083A (ja) * 1997-09-10 1999-03-23 Nof Corp エイコサペンタエン酸エステルの製造方法
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
JP2000159678A (ja) * 1998-11-30 2000-06-13 Nof Corp 皮膚外用剤組成物
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
JP2001131088A (ja) * 1999-11-02 2001-05-15 Kyurin:Kk シンドロームｘ症候群治療剤
CA2407895C (en) * 2000-05-05 2012-12-18 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders

Also Published As

Publication number Publication date
GB2388026B (en) 2006-02-08
GB2388026A (en) 2003-11-05
DE60329588D1 (de) 2009-11-19
JP4688203B2 (ja) 2011-05-25
ES2334656T3 (es) 2010-03-15
GB0210212D0 (en) 2002-06-12
GB0307625D0 (en) 2003-05-07
JP2005529903A (ja) 2005-10-06
NZ536507A (en) 2008-12-24

Similar Documents

Publication Publication Date Title
DE60212786D1 (de) Verwendung von polyungesättigten Fettsäuren zur primären Vorbeugung von kardiovaskulären Anfällen
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
BR0309740A (pt) Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
AU2003210210A1 (en) The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
BR9713479A (pt) Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico.
AU2003208920A1 (en) Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders
YU59303A (sh) Esencijalne n-3 masne kiseline u lečenju srčane insuficijencije i manjkavosti rada srca
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
EP1534261A4 (de) MIT EPA UND DHA ANGEREICHERTE OMEGA-3 ERGûNZUNG FÜR DIE BEHANDLUNG DES TROCKENEN AUGES, MEIBOMIANITIS UND XEROSTOMIE
AU2003217759A8 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
SE0303513D0 (sv) Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
PT1152755E (pt) Acidos gordos essenciais destinados a prevencao de acidentes cardio-vasculares
AU7175496A (en) Edible fat-spread
FR2860976B1 (fr) Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l'efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral.
WO2004112776A3 (en) Inflammatory disease treatment
DE60329588D1 (de) Verwendung von epa and dha zur sekundären prevention von schlaganfällen
ZA200502613B (en) Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
NO932984D0 (no) Fettsyrebehandling
SE9903915L (sv) Kolesterolsänkande och blodfettsänkande komposition
DE69809743D1 (de) An omega-3 ungesättigten fettsäuren angereicherte wachsester, ihre herstellung und verwendung
ATE312604T1 (de) Kombinationspräparat aus omega-3-fettsäuren und konjugierten linolsäuren zur behandlung immunologisch geprägter krankheitsbilder
IL158228A0 (en) Use of esters of long-chain fatty acids for treatment of autoimmune diseases
IL158227A0 (en) Fatty alcohols and fatty esters useful for treatment of inflammation
WO1999003456A3 (en) Method for prophylaxis or treatment of bone density loss
AU2003201112A1 (en) Oil including omega-3 fatty acids with therapeutic properties

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties